TR200102733T2 - IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri - Google Patents
IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleriInfo
- Publication number
- TR200102733T2 TR200102733T2 TR2001/02733T TR200102733T TR200102733T2 TR 200102733 T2 TR200102733 T2 TR 200102733T2 TR 2001/02733 T TR2001/02733 T TR 2001/02733T TR 200102733 T TR200102733 T TR 200102733T TR 200102733 T2 TR200102733 T2 TR 200102733T2
- Authority
- TR
- Turkey
- Prior art keywords
- treatment
- recombinant
- related disorders
- antagonists useful
- mabs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Kimerik, hümanize ve diger IL-18 mAb'ler, yüksek afiniteli nötrleyici mAb'lerden türetilmis olup, bunlari içeren farmasötik terkipler, tedavi ve teshis yöntemleri saglanmaktadir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12529999P | 1999-03-19 | 1999-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200102733T2 true TR200102733T2 (tr) | 2002-04-22 |
Family
ID=22419067
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/02733T TR200102733T2 (tr) | 1999-03-19 | 2000-03-17 | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri |
TR2002/02254T TR200202254T2 (tr) | 1999-03-19 | 2000-03-17 | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri. |
TR2002/02253T TR200202253T2 (tr) | 1999-03-19 | 2000-03-17 | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2002/02254T TR200202254T2 (tr) | 1999-03-19 | 2000-03-17 | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri. |
TR2002/02253T TR200202253T2 (tr) | 1999-03-19 | 2000-03-17 | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri |
Country Status (28)
Country | Link |
---|---|
US (2) | US6706487B1 (tr) |
EP (2) | EP1163271B1 (tr) |
JP (1) | JP2002542769A (tr) |
KR (1) | KR100697120B1 (tr) |
CN (1) | CN1246335C (tr) |
AR (1) | AR022952A1 (tr) |
AT (1) | ATE402191T1 (tr) |
AU (1) | AU764622B2 (tr) |
BR (1) | BR0008688A (tr) |
CA (1) | CA2368965C (tr) |
CO (1) | CO5470287A1 (tr) |
CY (1) | CY1108387T1 (tr) |
CZ (1) | CZ303704B6 (tr) |
DE (1) | DE60039589D1 (tr) |
DK (1) | DK1163271T3 (tr) |
ES (1) | ES2308974T3 (tr) |
HK (1) | HK1043798B (tr) |
HU (1) | HU228931B1 (tr) |
IL (1) | IL144995A0 (tr) |
MY (1) | MY124219A (tr) |
NO (1) | NO330391B1 (tr) |
NZ (1) | NZ513699A (tr) |
PL (1) | PL202396B1 (tr) |
PT (1) | PT1163271E (tr) |
SI (1) | SI1163271T1 (tr) |
TR (3) | TR200102733T2 (tr) |
WO (1) | WO2000056771A1 (tr) |
ZA (1) | ZA200107639B (tr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852266A (en) * | 1993-07-14 | 1998-12-22 | Hitachi, Ltd. | Vacuum circuit breaker as well as vacuum valve and electric contact used in same |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
DK1265928T3 (da) * | 2000-01-27 | 2010-11-15 | Medimmune Llc | RSV-neutraliserende antistoffer med ultra høj affinitet |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
KR101111103B1 (ko) * | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
TR200502508T2 (tr) * | 2000-02-21 | 2007-04-24 | Applied Research Systems Ar� Holding N.V. | IL-18 İnhibitörlerinin kullanımı. |
AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
WO2003083071A2 (en) * | 2002-03-26 | 2003-10-09 | Centocor, Inc. | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
AU2002343870A1 (en) | 2002-11-07 | 2004-06-07 | Kumamoto Technology And Industry Foundation | Transgenic mammal carrying ganp and utilization thereof |
AU2004235595C1 (en) | 2003-04-30 | 2009-09-24 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
AU2011224023C1 (en) * | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US7141382B1 (en) | 2004-10-12 | 2006-11-28 | Parikh Chirag R | Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality |
KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Il-13에 대항한 인간 항체 및 치료적 용도 |
BRPI0711908B8 (pt) * | 2006-05-25 | 2021-05-25 | Glaxo Group Ltd | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
GB0610438D0 (en) * | 2006-05-25 | 2006-07-05 | Glaxo Group Ltd | Immunoglobulins |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
AU2008312802A1 (en) * | 2007-10-19 | 2009-04-23 | Immunas Pharma, Inc. | Antibody capable of specifically binding to abeta oligomer, and use thereof |
US20100291071A1 (en) * | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
PT2246427T (pt) * | 2008-02-08 | 2017-03-03 | Immunas Pharma Inc | Anticorpos capazes de se ligar especificamente a oligómeros beta amilóides e a sua utilização |
WO2009127046A1 (en) * | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
WO2010020593A1 (en) * | 2008-08-18 | 2010-02-25 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
WO2010040736A2 (en) * | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
US8168165B2 (en) | 2008-12-23 | 2012-05-01 | Abbott Laboratories | Alkylated interleukin-18 compositions |
ES2641612T3 (es) | 2009-04-17 | 2017-11-10 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos |
KR20120034068A (ko) * | 2009-06-30 | 2012-04-09 | 가부시키가이샤 고센 | 라켓용 스트링과 그 제조 방법 및 이것을 장설한 라켓 |
CN102574915B (zh) | 2009-08-06 | 2014-10-22 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
JP5599454B2 (ja) | 2009-08-06 | 2014-10-01 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
EP3029070A1 (en) | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Therapeutic dll4 binding proteins |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
MX2012009167A (es) * | 2010-02-09 | 2012-08-23 | Glaxo Group Ltd | Tratamiento de un trastorno metabolico. |
EP2538965B1 (en) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
EP3680253A3 (en) * | 2010-03-02 | 2020-09-30 | AbbVie Inc. | Therapeutic dll4 binding proteins |
US20130109107A1 (en) * | 2010-05-25 | 2013-05-02 | The Regents Of The University Of Colorado | Diagnosis and treatment of autoimmune disease |
CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
CA2822515C (en) | 2010-12-20 | 2023-04-25 | Medimmune Limited | Anti-il-18 antibodies and their uses |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
EP2924117B1 (en) | 2012-11-21 | 2019-08-14 | KM Biologics Co., Ltd. | Novel human antibody against il-18 |
US10882905B2 (en) * | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
CA3183242A1 (en) * | 2020-06-18 | 2021-12-23 | Dallas Benjamin Flies | Compositions and methods for modulating flrt3 mediated signal transduction |
EP4371573A1 (en) | 2021-07-13 | 2024-05-22 | National University Corporation Tokai National Higher Education and Research System | Medicinal composition for treating inflammatory bowel disease |
CN117986360B (zh) * | 2024-02-01 | 2024-08-27 | 生物岛实验室 | Il18蛋白的特异性抗体及其制备方法与应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
EP0528767B1 (en) | 1991-08-21 | 2000-01-12 | Novartis AG | Antibody derivatives |
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
TW581771B (en) | 1994-11-15 | 2004-04-01 | Hayashibara Biochem Lab | Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide |
IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
FR2767697B1 (fr) | 1997-09-01 | 2000-05-05 | Boots Co Plc | Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee |
CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
-
2000
- 2000-03-16 AR ARP000101168A patent/AR022952A1/es active IP Right Grant
- 2000-03-17 NZ NZ513699A patent/NZ513699A/xx not_active IP Right Cessation
- 2000-03-17 PL PL350460A patent/PL202396B1/pl unknown
- 2000-03-17 EP EP00918152A patent/EP1163271B1/en not_active Expired - Lifetime
- 2000-03-17 BR BR0008688-6A patent/BR0008688A/pt not_active Application Discontinuation
- 2000-03-17 CZ CZ20013362A patent/CZ303704B6/cs not_active IP Right Cessation
- 2000-03-17 DK DK00918152T patent/DK1163271T3/da active
- 2000-03-17 AU AU39016/00A patent/AU764622B2/en not_active Expired
- 2000-03-17 CN CNB008077703A patent/CN1246335C/zh not_active Expired - Lifetime
- 2000-03-17 HU HU0200502A patent/HU228931B1/hu unknown
- 2000-03-17 SI SI200031002T patent/SI1163271T1/sl unknown
- 2000-03-17 PT PT00918152T patent/PT1163271E/pt unknown
- 2000-03-17 KR KR1020017011872A patent/KR100697120B1/ko active IP Right Grant
- 2000-03-17 CO CO00019489A patent/CO5470287A1/es active IP Right Grant
- 2000-03-17 TR TR2001/02733T patent/TR200102733T2/tr unknown
- 2000-03-17 TR TR2002/02254T patent/TR200202254T2/tr unknown
- 2000-03-17 ES ES00918152T patent/ES2308974T3/es not_active Expired - Lifetime
- 2000-03-17 TR TR2002/02253T patent/TR200202253T2/tr unknown
- 2000-03-17 JP JP2000606631A patent/JP2002542769A/ja active Pending
- 2000-03-17 WO PCT/US2000/007349 patent/WO2000056771A1/en active IP Right Grant
- 2000-03-17 DE DE60039589T patent/DE60039589D1/de not_active Expired - Lifetime
- 2000-03-17 MY MYPI20001044A patent/MY124219A/en unknown
- 2000-03-17 US US09/914,695 patent/US6706487B1/en not_active Expired - Lifetime
- 2000-03-17 IL IL14499500A patent/IL144995A0/xx not_active IP Right Cessation
- 2000-03-17 AT AT00918152T patent/ATE402191T1/de active
- 2000-03-17 CA CA2368965A patent/CA2368965C/en not_active Expired - Lifetime
- 2000-03-17 EP EP08157217A patent/EP1961768A1/en not_active Withdrawn
-
2001
- 2001-09-17 ZA ZA200107639A patent/ZA200107639B/en unknown
- 2001-09-18 NO NO20014524A patent/NO330391B1/no not_active IP Right Cessation
-
2002
- 2002-05-21 HK HK02103813.7A patent/HK1043798B/zh not_active IP Right Cessation
-
2004
- 2004-01-22 US US10/762,629 patent/US20040141964A1/en not_active Abandoned
-
2008
- 2008-09-30 CY CY20081101085T patent/CY1108387T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
EP1470146B8 (en) | Antibodies against the muc18 antigen | |
WO2003057837A8 (en) | Methods for using anti-muc18 antibodies | |
EP1467757A4 (en) | USE OF ANTIBODIES TO THE MUC18 ANTIGEN | |
RS80704A (en) | ANTI- av?6.ANTIBODIES | |
HUP0303952A2 (hu) | Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre | |
DE60141043D1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
IL148079A0 (en) | Human ctla-4 antibodies and compositions containing the same | |
WO2004047728A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004039956A3 (en) | Compositions and methods for the treatment of immune related diseases | |
ZA200508389B (en) | Humanized antibodies to interferon alpha receptor-1(IFNAR-1) | |
DE69934515D1 (de) | Humanisierte monoklonale integrin antikörper | |
WO2004108766A3 (en) | Anti-hgf-r antibodies and their use | |
FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
EA200201138A1 (ru) | Пептид, модулирующий рецептор тромбопоэтина | |
WO2003010291A3 (en) | Treatment of immune disorders and b cell disorders | |
WO2004031105A3 (en) | Use of a33 antigens and jam-it | |
ATE235551T1 (de) | Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen | |
WO2001072334A3 (en) | Methods for treating disease with antibodies to cxcr3 | |
WO2005058358A3 (en) | Use of agents derived from ceacam1 for the treatment of inflammatory diseases | |
WO2003087841A3 (en) | An ephrin-b receptor protein involved in carcinoma | |
DE59911103D1 (de) | ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1) | |
WO2001066740A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004004649A3 (en) | Compositions and methods for the treatment of immune related diseases |